Journal for ImmunoTherapy of Cancer: 10 (1)

Basic tumor immunology

Original research: TSH-TSHR axis promotes tumor immune evasion (31 January, 2022)
Zhenghao Wu, Zihan Xi, Yunxiao Xiao, Xiangwang Zhao, Jiexiao Li, Nan Feng, Longqing Hu, Renjing Zheng, Ning Zhang, Shuntao Wang, Tao Huang
Original research:
Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56^brightCD16⁻ subset
(28 January, 2022)
Irene Veneziani, Claudia Alicata, Andrea Pelosi, Nadine Landolina, Biancamaria Ricci, Valentina D'Oria, Anna Fagotti, Giovanni Scambia, Lorenzo Moretta, Enrico Maggi
Original research:
CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T_H1 and T_H9 cells
(28 January, 2022)
Isis Benoit-Lizon, Elise Jacquin, Thaiz Rivera Vargas, Corentin Richard, Aurélie Roussey, Ludivine Dal Zuffo, Tiffany Martin, Andréa Melis, Daria Vinokurova, Sayyed Hamed Shahoei, Alvaro Baeza Garcia, Cassandre Pignol, Stéphane Giorgiutti, Raphaël Carapito, Romain Boidot, Frédérique Végran, Richard A Flavell, Bernhard Ryffel, Eric R Nelson, Pauline Soulas-Sprauel, Toby Lawrence, Lionel Apetoh
Original research: CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor (21 January, 2022)
Serena Zilio, Silvio Bicciato, Donald Weed, Paolo Serafini
Original research: CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors (17 January, 2022)
Chantal L Duurland, Saskia J Santegoets, Ziena Abdulrahman, Nikki M Loof, Gregor Sturm, Tom H Wesselink, Ramon Arens, Sanne Boekestijn, Ilina Ehsan, Mariette I E van Poelgeest, Francesca Finotello, Hubert Hackl, Zlatko Trajanoski, Peter ten Dijke, Veronique M Braud, Marij J P Welters, Sjoerd H van der Burg
Original research: Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer (17 January, 2022)
Kazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, Kazumasa Komura, Takuo Hayashi, Wataru Fukuokaya, Ayako Ura, Taizo Uchimoto, Ko Nakamura, Tatsuo Fukushima, Yusuke Yano, Nobushige Takahashi, Keita Nakamori, Shoko Kinoshita, Tomohisa Matsunaga, Takeshi Tsutsumi, Takuya Tsujino, Kohei Taniguchi, Tomohito Tanaka, Hirofumi Uehara, Kiyoshi Takahara, Teruo Inamoto, Yoshinobu Hirose, Takahiro Kimura, Shin Egawa, Haruhito Azuma
Original research: Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer (12 January, 2022)
Francesco De Sanctis, Alessia Lamolinara, Federico Boschi, Chiara Musiu, Simone Caligola, Rosalinda Trovato, Alessandra Fiore, Cristina Frusteri, Cristina Anselmi, Ornella Poffe, Tiziana Cestari, Stefania Canè, Silvia Sartoris, Rosalba Giugno, Giulia Del Rosario, Barbara Zappacosta, Francesco Del Pizzo, Matteo Fassan, Erica Dugnani, Lorenzo Piemonti, Emanuela Bottani, Ilaria Decimo, Salvatore Paiella, Roberto Salvia, Rita Teresa Lawlor, Vincenzo Corbo, Youngkyu Park, David A Tuveson, Claudio Bassi, Aldo Scarpa, Manuela Iezzi, Stefano Ugel, Vincenzo Bronte
Original research: Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments (11 January, 2022)
Julia Moreno-Vicente, Jane E Willoughby, Martin C Taylor, Steven G Booth, Vikki L English, Emily L Williams, Christine A Penfold, C Ian Mockridge, Tatyana Inzhelevskaya, Jinny Kim, H T Claude Chan, Mark S Cragg, Juliet C Gray, Stephen A Beers
Original research: G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes (11 January, 2022)
Chunwan Lu, Dafeng Yang, John D Klement, Yolonda L Colson, Nicholas H Oberlies, Cedric J Pearce, Aaron H Colby, Mark W Grinstaff, Han-Fei Ding, Huidong Shi, Kebin Liu
Original research: Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma (7 January, 2022)
Boyuan Liu, Zewei Zhou, Yu Jin, Jinying Lu, Dongju Feng, Rui Peng, Hua Sun, Xiaoxin Mu, Changxian Li, Yun Chen
Original research:
TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8⁺ T cell and XCR1⁺ dendritic cell spatial co-localization
(5 January, 2022)
Alycia Gardner, Álvaro de Mingo Pulido, Kay Hänggi, Sarah Bazargan, Alexis Onimus, Agnieszka Kasprzak, Jose R Conejo-Garcia, Katarzyna A Rejniak, Brian Ruffell

Clinical/translational cancer immunotherapy

Original research: A very long-acting IL-15: implications for the immunotherapy of cancer (31 January, 2022)
John A Hangasky, Wei Chen, Sigrid P Dubois, Anusara Daenthanasanmak, Jürgen R Müller, Ralph Reid, Thomas A Waldmann, Daniel V Santi
Original research: Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition (28 January, 2022)
Nilasha Ghosh, Michael Postow, Chengsong Zhu, Deanna Jannat-Khah, Quan-Zhen Li, Greg Vitone, Karmela K Chan, Anne R Bass
Original research:
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10⁺ advanced non-small cell lung cancer
(27 January, 2022)
George R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, Victor Moreno, Justin Gainor, Martin J Edelman, John V Heymach, Ramaswamy Govindan, Carlos Bachier, Bernard Doger de Spéville, Matthew J Frigault, Anthony J Olszanski, Vincent K Lam, Natalie Hyland, Jean-Marc Navenot, Svetlana Fayngerts, Zohar Wolchinsky, Robyn Broad, Dzmitry Batrakou, Melissa M Pentony, Joseph P Sanderson, Andrew Gerry, Diane Marks, Jane Bai, Tom Holdich, Elliot Norry, Paula M Fracasso
Original research: Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer (25 January, 2022)
Markus Hecht, Markus Eckstein, Sandra Rutzner, Jens von der Grün, Thomas Illmer, Gunther Klautke, Simon Laban, Matthias G Hautmann, Thomas B Brunner, Bálint Tamaskovics, Axel Hinke, Jian-Guo Zhou, Benjamin Frey, Anna-Jasmina Donaubauer, Ina Becker, Sabine Semrau, Arndt Hartmann, Panagiotis Balermpas, Wilfried Budach, Udo S Gaipl, Heinrich Iro, Antoniu-Oreste Gostian, Rainer Fietkau
Original research: Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary (24 January, 2022)
Ahmad A Tarhini, Sandra J Lee, Aik-Choon Tan, Issam M El Naqa, F Stephen Hodi, Lisa H Butterfield, William A LaFramboise, Walter J Storkus, Arivarasan D Karunamurthy, Jose R Conejo-Garcia, Patrick Hwu, Howard Streicher, Vernon K Sondak, John M Kirkwood
Original research: Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses (24 January, 2022)
Claire F Friedman, Christine Spencer, Christopher R Cabanski, Katherine S Panageas, Daniel K Wells, Antoni Ribas, Hussein Tawbi, Katy Tsai, Michael Postow, Alexander Shoushtari, Paul Chapman, Joyson Karakunnel, Samantha Bucktrout, Pier Gherardini, Travis J Hollmann, Richard O Chen, Margaret Callahan, Theresa LaVallee, Ramy Ibrahim, Jedd Wolchok
Original research: Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma (24 January, 2022)
Ivelina Spassova, Selma Ugurel, Linda Kubat, Lisa Zimmer, Patrick Terheyden, Annalena Mohr, Hannah Björn Andtback, Lisa Villabona, Ulrike Leiter, Thomas Eigentler, Carmen Loquai, Jessica C Hassel, Thilo Gambichler, Sebastian Haferkamp, Peter Mohr, Claudia Pfoehler, Lucie Heinzerling, Ralf Gutzmer, Jochen S Utikal, Kai Horny, Hans-Ulrich Schildhaus, Daniel Habermann, Daniel Hoffmann, Dirk Schadendorf, Jürgen Christian Becker
Original research: Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study (21 January, 2022)
Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M O’Malley, Vanessa Samouelian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath III, Wei Guo, Ellie Im, Sybil Zildjian, Xinwei Han, Tao Duan, Jennifer Veneris, Bhavana Pothuri
Original research: JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy (21 January, 2022)
Gabrielle Leclercq, Hélène Haegel, Alberto Toso, Tina Zimmermann, Luke Green, Nathalie Steinhoff, Johannes Sam, Vesna Pulko, Anneliese Schneider, Anna Maria Giusti, John Challier, Anne Freimoser-Grundschober, Laurent Larivière, Alex Odermatt, Martin Stern, Pablo Umana, Marina Bacac, Christian Klein
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study (20 January, 2022)
Paolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, Todd M Bauer, Marcello Tucci, Antoine Italiano, Roberto Iacovelli, Wu-Chou Su, Christophe Massard, Mansoor Saleh, Gennaro Daniele, Alastair Greystoke, Martin Gutierrez, Shubham Pant, Ying-Chun Shen, Matteo Perrino, Robin Meng, Giovanni Abbadessa, Helen Lee, Yingwen Dong, Marielle Chiron, Rui Wang, Laure Loumagne, Lucie Lépine, Johann de Bono
Original research: Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders (20 January, 2022)
Liye Zhou, Zexian Zeng, Ann Marie Egloff, Fan Zhang, Fei Guo, Katie M Campbell, Peter Du, Jingxin Fu, Paul Zolkind, Xiaojing Ma, Zhe Zhang, Yi Zhang, Xiaoqing Wang, Shengqing Gu, Rachel Riley, Yasutaka Nakahori, Joshua Keegan, Robert Haddad, Jonathan D Schoenfeld, Obi Griffith, Robert T Manguso, James A Lederer, X Shirley Liu, Ravindra Uppaluri
Original research: Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy (20 January, 2022)
Ying Jing, Xue Chen, Kunyan Li, Yaoming Liu, Zhao Zhang, Yiqing Chen, Yuan Liu, Yushu Wang, Steven H Lin, Lixia Diao, Jing Wang, Yanyan Lou, Douglas B Johnson, Xiang Chen, Hong Liu, Leng Han
Original research: Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate (20 January, 2022)
Rosemina Merchant, Carole Galligan, Manjunatha Ankathatti Munegowda, L Bruce Pearce, Peter Lloyd, Paul Smith, Fahar Merchant, Minh D To
Original research: Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity (17 January, 2022)
Shinya Abe, Hiroshi Nagata, Erika J Crosby, Yoshiyuki Inoue, Kensuke Kaneko, Cong-Xiao Liu, Xiao Yang, Tao Wang, Chaitanya R Acharya, Pankaj Agarwal, Joshua Snyder, William Gwin, Michael A Morse, Pei Zhong, Herbert Kim Lyerly, Takuya Osada
Original research: Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma (12 January, 2022)
Weixiong Yang, Xiangbin Xing, Sai-Ching Jim Yeung, Siyu Wang, Wenfang Chen, Yong Bao, Fang Wang, Shiting Feng, Fang Peng, Xiaoyan Wang, Shuling Chen, Minghui He, Ning Zhang, Honglei Wang, Bo Zeng, Zhenguo Liu, Biniam Kidane, Christopher W Seder, Kazuo Koyanagi, Yaron Shargall, Honghe Luo, Sui Peng, Chao Cheng
Original research: Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia (11 January, 2022)
Meghali Goswami, Gege Gui, Laura W Dillon, Katherine E Lindblad, Julie Thompson, Janet Valdez, Dong-Yun Kim, Jack Y Ghannam, Karolyn A Oetjen, Christin B Destefano, Dana M Smith, Hanna Tekleab, Yeusheng Li, Pradeep Dagur, Thomas Hughes, Jennifer L Marté, Jaydira del Rivero, Joanna Klubo-Gwiezdzinksa, James L Gulley, Katherine R Calvo, Catherine Lai, Christopher S Hourigan
Original research: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment (11 January, 2022)
Mathieu Seyfrid, William Thomas Maich, Muhammad Vaseem Shaikh, Nazanin Tatari, Deepak Upreti, Deween Piyasena, Minomi Subapanditha, Neil Savage, Dillon McKenna, Nicholas Mikolajewicz, Hong Han, Chirayu Chokshi, Laura Kuhlmann, Amanda Khoo, Sabra Khalid Salim, Blessing Archibong-Bassey, William Gwynne, Kevin Brown, Nadeem Murtaza, David Bakhshinyan, Parvez Vora, Chitra Venugopal, Jason Moffat, Thomas Kislinger, Sheila Singh
Original research: Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma (11 January, 2022)
Mona O Mohsen, Daniel E Speiser, Justine Michaux, HuiSong Pak, Brian J Stevenson, Monique Vogel, Varghese Philipose Inchakalody, Simone de Brot, Said Dermime, Georges Coukos, Michal Bassani-Sternberg, Martin F Bachmann
Original research: Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study (11 January, 2022)
Lingfang Xia, Jin Peng, Ge Lou, Mei Pan, Qi Zhou, Wenjing Hu, Huirong Shi, Li Wang, Yunong Gao, Jianqing Zhu, Yu Zhang, Rong Sun, Xianfeng Zhou, Quanren Wang, Xiaohua Wu
Original research: Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling (6 January, 2022)
Shiping Jiao, Qing Xiong, Meisi Yan, Xiaolu Zhan, Zhenhuang Yang, Cheng Peng, Beicheng Sun, Da Pang, Tong Liu
Original research: Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study (6 January, 2022)
Akie Kimura Yoshikawa, Kensei Yamaguchi, Kei Muro, Atsuo Takashima, Takashi Ichimura, Daisuke Sakai, Shigenori Kadowaki, Keisho Chin, Toshihiro Kudo, Seiichiro Mitani, Shigehisa Kitano, Dung Thai, Marianna Zavodovskaya, JieJane Liu, Narikazu Boku, Taroh Satoh

Case report

Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer (31 January, 2022)
Pashtoon Murtaza Kasi, Griffin Budde, Michael Krainock, Vasily N Aushev, Allyson Koyen Malashevich, Meenakshi Malhotra, Perry Olshan, Paul R Billings, Alexey Aleshin

Commentaries

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment (31 January, 2022)
Elisabetta Gambale, Sara Fancelli, Enrico Caliman, Maria Cristina Petrella, Laura Doni, Serena Pillozzi, Lorenzo Antonuzzo
Mac Cheever (1944–2021): a tribute to a life of achievement and service (12 January, 2022)
Philip D Greenberg, Mary L Disis, Kim A Margolin, Lynn M Matrisian, Paul M Sondel

Immune cell therapies and immune cell engineering

Original research: Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling (31 January, 2022)
Kenichi Makino, Mark D Long, Ryutaro Kajihara, Satoko Matsueda, Takaaki Oba, Kazunori Kanehira, Song Liu, Fumito Ito
Original research: Intermediate monocytes induced by IFN-γ inhibit cancer metastasis by promoting NK cell activation through FOXO1 and interleukin-27 (28 January, 2022)
Rikang Wang, Weili Bao, Mouli Pal, Yunfeng Liu, Karina Yazdanbakhsh, Hui Zhong
Original research: Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells (28 January, 2022)
Talar Tokatlian, Grace E Asuelime, Jee-Young Mock, Breanna DiAndreth, Shruti Sharma, Dora Toledo Warshaviak, Mark E Daris, Kristian Bolanos, Breanna L Luna, Martin S Naradikian, Kiran Deshmukh, Agnes E Hamburger, Alexander Kamb
Original research: Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies (27 January, 2022)
Jeong A Park, Nai-Kong V Cheung
Original research: PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells (25 January, 2022)
Malgorzata Bajor, Agnieszka Graczyk-Jarzynka, Katsiaryna Marhelava, Anna Burdzinska, Angelika Muchowicz, Agnieszka Goral, Andriy Zhylko, Karolina Soroczynska, Kuba Retecki, Marta Krawczyk, Marta Klopotowska, Zofia Pilch, Leszek Paczek, Karl-Johan Malmberg, Sébastien Wälchli, Magdalena Winiarska, Radoslaw Zagozdzon
Original research: Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors (13 January, 2022)
Jiemiao Hu, Qing Yang, Wendong Zhang, Hongwei Du, Yuhui Chen, Qingnan Zhao, Long Dao, Xueqing Xia, Fowlkes Natalie Wall, Zhongting Zhang, Kris Mahadeo, Richard Gorlick, S Kopetz, Gianpietro Dotti, Shulin Li
Original research: Large-scale manufacturing and characterization of CMV-CD19CAR T cells (13 January, 2022)
Xiuli Wang, Ryan Urak, Miriam Walter, Min Guan, Tianxu Han, Vibhuti Vyas, Sheng-Hsuan Chien, Brenna Gittins, Mary C Clark, Sally Mokhtari, Angelo Cardoso, Don J Diamond, John Zaia, Stephen J Forman, Ryotaro Nakamura
Original research: Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer (12 January, 2022)
Loïc Reppel, Ourania Tsahouridis, Jason Akulian, Ian J Davis, Hong Lee, Giovanni Fucà, Jared Weiss, Gianpietro Dotti, Chad V Pecot, Barbara Savoldo
Original research:
B cells imprint adoptively transferred CD8⁺ T cells with enhanced tumor immunity
(11 January, 2022)
Aubrey S Smith, Hannah M Knochelmann, Megan M Wyatt, Guillermo O Rangel Rivera, Amalia M Rivera-Reyes, Connor J Dwyer, Michael B Ware, Anna C Cole, David M Neskey, Mark P Rubinstein, Bei Liu, Jessica E Thaxton, Eric Bartee, Chrystal M Paulos
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) (7 January, 2022)
Marc Wehrli, Kathleen Gallagher, Yi-Bin Chen, Mark B Leick, Steven L McAfee, Areej R El-Jawahri, Zachariah DeFilipp, Nora Horick, Paul O'Donnell, Thomas Spitzer, Bimal Dey, Daniella Cook, Michael Trailor, Kevin Lindell, Marcela V Maus, Matthew J Frigault
Original research: Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial (6 January, 2022)
Lukas Rob, David Cibula, Pawel Knapp, Peter Mallmann, Jaroslav Klat, Lubos Minar, Pavel Bartos, Josef Chovanec, Petr Valha, Marek Pluta, Zdenek Novotny, Jiri Spacek, Bohuslav Melichar, Dariusz Kieszko, Jitka Fucikova, Tereza Hrnciarova, Roman Pawel Korolkiewicz, Marek Hraska, Jirina Bartunkova, Radek Spisek

Immunotherapy biomarkers

Original research: Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy (31 January, 2022)
Jiawei Shi, Junwei Liu, Xiaoxuan Tu, Bin Li, Zhou Tong, Tian Wang, Yi Zheng, Hongyu Shi, Xun Zeng, Wei Chen, Weiwei Yin, Weijia Fang
Original research: Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors (31 January, 2022)
Razvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Lei Xu, Xiao Qiao Liu, Andrey Loboda, Lixin Lang, Fan Jin, Eric H Rubin, Alexandra Snyder, Jared Lunceford
Original research: Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better (31 January, 2022)
Ming Zheng
Original research: Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer (27 January, 2022)
Brie Chun, Joanna Pucilowska, ShuChing Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A Fields, Valerie Conrad, Mark Schmidt, Walter J Urba, Alison K Conlin, Heather L McArthur, David B Page
Original research: Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature (10 January, 2022)
Francois Bertucci, Vincent Niziers, Alexandre de Nonneville, Pascal Finetti, Léna Mescam, Olivier Mir, Antoine Italiano, Axel Le Cesne, Jean-Yves Blay, Michele Ceccarelli, Davide Bedognetti, Daniel Birnbaum, Emilie Mamessier

Letter

Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al
(18 January, 2022)
Jeffrey Weber, Mario Mandala, Paolo Antonio Ascierto, James Larkin
Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 (18 January, 2022)
Alexander Eggermont, Michal Kicinski, Stefan Suciu

Oncolytic and local immunotherapy

Original research: CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model (27 January, 2022)
Ruikun Wang, Jingru Chen, Wei Wang, Zhuoqian Zhao, Haoran Wang, Shiyu Liu, Fan Li, Yajuan Wan, Jie Yin, Rui Wang, Yuanke Li, Cuizhu Zhang, Hongkai Zhang, Youjia Cao
Original research:
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8⁺ T cell immunity to reject ‘cold’ tumors
(19 January, 2022)
Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L Cleary, Mimoza Bodén, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Eric Quéméneur, Björn Frendéus
Original research: Short-course neoadjuvant in situ vaccination for murine melanoma (17 January, 2022)
Taylor J Aiken, David Komjathy, Matthew Rodriguez, Ashley Stuckwisch, Arika Feils, Vladimir Subbotin, Jen Birstler, Stephen D Gillies, Alexander L Rakhmilevich, Amy K Erbe, Paul M Sondel
Original research: Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models (11 January, 2022)
Marilin S Koch, Mykola Zdioruk, Michal O Nowicki, Alec M Griffith, Estuardo Aguilar, Laura K Aguilar, Brian W Guzik, Francesca Barone, Paul P Tak, Ghazaleh Tabatabai, James A Lederer, E Antonio Chiocca, Sean Lawler
Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironment (5 January, 2022)
Fengguang Guo, Jugal K Das, Koichi S Kobayashi, Qing-Ming Qin, Thomas A Ficht, Robert C Alaniz, Jianxun Song, Paul De Figueiredo

Reviews

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition (27 January, 2022)
Meagan-Helen Henderson Berg, Sonia Victoria del Rincón, Wilson H Miller
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies (25 January, 2022)
Olivier Michielin, Aly-Khan Lalani, Caroline Robert, Padmanee Sharma, Solange Peters
Immuno-oncology trends: preclinical models, biomarkers, and clinical development (12 January, 2022)
Maryland Rosenfeld Franklin, Suso Platero, Kamal S Saini, Giuseppe Curigliano, Steven Anderson
Role of Fcγ receptors in HER2-targeted breast cancer therapy (6 January, 2022)
Antonino Musolino, William J Gradishar, Hope S Rugo, Jeffrey L Nordstrom, Edwin P Rock, Fernanda Arnaldez, Mark D Pegram

Main menu

Table of contents

January 2022 - Volume 10 - 1

Basic tumor immunology

Clinical/translational cancer immunotherapy

Case report

Commentaries

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Letter

Oncolytic and local immunotherapy

Reviews

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

January 2022 - Volume 10 - 1

Basic tumor immunology

Clinical/translational cancer immunotherapy

Case report

Commentaries

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Letter

Oncolytic and local immunotherapy

Reviews